Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624364 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL3835254 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL3199894 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL3199882 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL26654416 | 0.99 | CASP3 (0.58) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL26654411 | 0.99 | CASP3 (0.58) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL5846051 | 0.93 | CASP3 (0.55) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL3230119 | 0.92 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL7198189 | 0.92 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL3725037 | 0.92 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368680-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4520748-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-12 | — | — | EP | disclosed |
| CN-119156373-A | Method for producing salts of amino acids or salts of peptide compounds or solvates of any of the salts comprising a lithium salt precipitation step | 中外制药株式会社 | 2024-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368680-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | NPPA, DNPEP, NPEPPS | CASP3 2635/4885KMT2A 3331/4885MDM4 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.